

Andrea Spallanzani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/935861/publications.pdf>

Version: 2024-02-01

46
papers

1,192
citations

394421

19
h-index

395702

33
g-index

47
all docs

47
docs citations

47
times ranked

2177
citing authors

#	ARTICLE	IF	CITATIONS
1	New Horizons for Personalised Treatment in Gastroesophageal Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 311.	2.4	3
2	Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy. <i>Cancer Management and Research</i> , 2022, Volume 14, 983-993.	1.9	0
3	Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 73-79.	3.0	3
4	Multicentre match-paired analysis of advanced biliary cancer long-term survivors: The BILONG study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101955.	1.5	1
5	Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience. <i>Future Oncology</i> , 2022, 18, 2651-2659.	2.4	0
6	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). <i>Cancers</i> , 2021, 13, 1304.	3.7	2
7	The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 1705.	2.4	6
8	Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial. <i>European Journal of Cancer</i> , 2021, 148, 422-429.	2.8	8
9	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	3.7	31
10	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 150, 155-167.	2.8	45
11	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	1.6	49
12	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, Real-Life, Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	2.3	8
13	Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board. <i>Nutrients</i> , 2021, 13, 3522.	4.1	22
14	TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 4500-4514.	1.4	0
15	Magnetic resonance imaging performed before and after preoperative chemoradiotherapy in rectal cancer: predictive factors of recurrence and prognostic significance of MR-detected extramural venous invasion. <i>Abdominal Radiology</i> , 2020, 45, 2941-2949.	2.1	23
16	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020, 40, 704-711.	3.9	42
17	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020, 25, 803-809.	3.7	26
18	mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus. <i>Cancers</i> , 2020, 12, 1201.	3.7	6

#	ARTICLE	IF	CITATIONS
19	Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 82-90.e9.	2.3	6
20	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020, 25, 481-487.	3.7	77
21	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020, 25, 259-265.	3.7	27
22	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020, 12, 1022.	3.7	16
23	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020, 25, 780-786.	3.7	14
24	Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11-11.	1.6	46
25	Synchronous and metachronous colorectal liver metastases: impact of primary tumor location on patterns of recurrence and survival after hepatic resection. <i>Acta Biomedica</i> , 2020, 92, e2021061.	0.3	0
26	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	2.8	51
27	The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 84-90.	2.8	21
28	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5369.	4.1	88
29	Cannonball-Like Lung Nodules in a Patient With a Colorectal Tumor. <i>Chest</i> , 2019, 156, e85-e89.	0.8	2
30	<p>Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CI: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4357-4369.	1.9	17
31	The treatment of rectal cancer with synchronous liver metastases: A matter of strategy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 91-95.	4.4	9
32	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019, 19, 283.	2.6	12
33	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , 2019, 24, 185-192.	3.7	89
34	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1479-1482.	1.0	10
35	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. <i>European Journal of Endocrinology</i> , 2019, 181, 681-689.	3.7	30
36	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018, 18, 198-203.	1.1	18

#	ARTICLE	IF	CITATIONS
37	Histopathological variables in liver metastases of patients with stage IV colorectal cancer: potential prognostic relevance of poorly differentiated clusters. <i>Human Pathology</i> , 2018, 78, 115-124.	2.0	13
38	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. <i>Targeted Oncology</i> , 2018, 13, 227-234.	3.6	33
39	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. <i>Endocrine</i> , 2018, 60, 490-498.	2.3	59
40	To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 154-160.	4.4	5
41	Lenvatinib as a therapy for unresectable hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1069-1076.	2.4	25
42	Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient. <i>Gastrointestinal Tumors</i> , 2018, 5, 14-20.	0.7	6
43	Immunotherapy in the treatment of colorectal cancer: a new kid on the block. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 28.	0.8	7
44	A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). <i>Clinical Colorectal Cancer</i> , 2017, 16, 410-415.e1.	2.3	7
45	The evolving role of microsatellite instability in colorectal cancer: A review. <i>Cancer Treatment Reviews</i> , 2016, 51, 19-26.	7.7	207
46	The somatic affairs of <i>BRAF</i> : tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. <i>Journal of Clinical Pathology</i> , 2013, 66, 441-445.	2.0	21